The antimicrobial sanitary pad market is witnessing a significant update in technical benchmarks. Released in August 2026, the group standard T/CIAA 008—2026 for antimicrobial sanitary pads, pantyliners, and period pants introduces for the first time the concept of 'long-lasting antimicrobial' efficacy, with test conditions simulating real use at (36±1)°C for at least 8 hours using bovine serum albumin. This shift means antibacterial performance is no longer a static factory-gate metric but a dynamic evaluation closer to actual usage scenarios.
Standard Upgrade: From 'Antibacterial' to 'Long-Lasting Efficacy'
The new standard is administered by the Zhongguancun Huizhi Antimicrobial New Materials Industry Technology Innovation Alliance, with drafting contributions from Henan Shulai, Guangdong Institute of Microbiology, SGS, and Jinda Nano Technology. The revision focuses on three core areas: definitions, requirements, and test methods. The definition now expands 'bacteriostatic sanitary pads' to 'antimicrobial sanitary pads, pantyliners, and period pants,' and adds a new term 'long-lasting antimicrobial' (bacteriostatic), which specifies evaluation by adding bovine serum albumin to the skin-contact layer and incubating at (36±1)°C for no less than 8 hours to simulate the effect under menstrual fluid or body fluid interference.
In terms of requirements, the new standard aligns with GB 15979-2024 for disposable sanitary products, covering antibacterial performance, bacteriostatic performance, stability, and toxicology, while additionally incorporating long-lasting antimicrobial requirements. Test methods have been revised accordingly, with new procedures for long-lasting efficacy. This underscores a tighter integration between group standards and national mandatory hygiene standards, offering enterprises a clearer compliance pathway.
Industry Impact: Higher Technical Barriers, Accelerated Supply Chain Transmission
For manufacturers of sanitary pads, pantyliners, and period pants, the new standard demands that R&D and quality control incorporate simulated-use dimensions. Previously, companies only needed to prove antibacterial or bacteriostatic function under laboratory conditions; now they must verify sustained efficacy in the presence of simulated body fluids and body temperature. This directly influences the selection of antimicrobial agents, their dosage, and release mechanisms, thereby affecting upstream suppliers of antimicrobial materials. For instance, silver-based, chitosan, or quaternary ammonium agents will be screened for long-term efficacy and safety rather than just initial kill rates.
From the procurement perspective, brands will consider 'long-lasting antimicrobial' test reports as a new hard requirement when selecting contract manufacturers or raw material suppliers. This may impose higher testing costs and technical upgrade pressure on SMEs, while capable leading companies could expand market share. The revision also signals that functional claims in hygiene products are moving from concept to data-driven validation, enhancing consumer trust in 'antibacterial' labels.
For downstream channels, the new standard helps reduce exaggerated claims and false labeling, promoting a more standardized and high-quality market evolution. For exporters, products meeting T/CIAA standards may be more persuasive in overseas markets, particularly in Southeast Asia and the Middle East. However, since definitions of 'long-lasting antimicrobial' vary across countries, exporters must still monitor target market regulations.